Sympathetic nervous modulation of the skin innate and adaptive immune response to peptidoglycan but not lipopolysaccharide: involvement of beta-adrenoceptors and relevance in inflammatory diseases.
Disorders of the skin immune activity are implicated in the pathogenesis of acquired inflammatory skin disorders. Inflammatory diseases including psoriasis, atopic dermatitis, lichen planus and vitiligo have also been associated with local alterations of adrenergic mechanisms and emotional stress. Here we show that the beta-adrenergic receptors antagonist propranolol along with peptidoglycan, but not LPS, combined with intradermal injection of a soluble protein, shifted the recall memory response to the Th1 type. The specific beta2-AR antagonist ICI 118,551 did not reproduce this effect suggesting that inhibition of both beta1- and beta2-AR caused the Th1 polarization. The underlying mechanism included enhanced local expression of IFN-gamma, IL-12 and IL-23 as well as of IFN-beta and CXCR3 ligands during the innate phase of the response which resulted in an increase of antigen-positive plasmacytoid dendritic cells (pDCs) in the draining lymph node. In particular, modulation of inflammatory cytokines, and IFN-beta inducible genes expression appeared to involve also the beta1-AR. Plasmacytoid dendritic cells and IL-23 were recently reported to play a central role in the pathogenesis of Th1-sustained inflammatory skin diseases such as psoriasis. Thus, primary beta-adrenoceptors signaling defects or altered sympathetic nervous activity together with selected pattern recognition receptors activation might serve as initiation and/or persistence factors for numerous Th1-sustained inflammatory skin diseases.
Manni
Michela
M
Istituto Cantonale di Patologia, Center for Experimental Pathology, Via in Selva 24, P.O. Box, 6601 Locarno, Switzerland.
Maestroni
Georges J M
GJ
D000222:Adaptation, Physiological; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D015784:Betaxolol / Q000494:pharmacology; D002465:Cell Movement / Q000187:drug effects; D003713:Dendritic Cells / Q000187:drug effects / Q000276:immunology; D005260:Female; D007113:Immunity, Innate / Q000187:drug effects; D007114:Immunization; D007156:Immunologic Memory / Q000187:drug effects; D007249:Inflammation / Q000276:immunology; D007271:Injections, Intradermal; D016899:Interferon-beta / Q000378:metabolism; D008024:Ligands; D008070:Lipopolysaccharides / Q000008:administration & dosage / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008822:Mice, Transgenic; D010047:Ovalbumin / Q000276:immunology; D010457:Peptidoglycan / Q000008:administration & dosage / Q000276:immunology* / Q000494:pharmacology; D011412:Propanolamines / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D011943:Receptors, Adrenergic, beta / Q000378:metabolism; D054367:Receptors, CXCR3 / Q000378:metabolism; D012867:Skin / Q000166:cytology / Q000276:immunology* / Q000378:metabolism; D012871:Skin Diseases / Q000276:immunology; D013564:Sympathetic Nervous System / Q000502:physiology*; D018417:Th1 Cells / Q000276:immunology
D000319:Adrenergic beta-Antagonists; C515188:Cxcr3 protein, mouse; D008024:Ligands; D008070:Lipopolysaccharides; D010457:Peptidoglycan; D011412:Propanolamines; D011943:Receptors, Adrenergic, beta; D054367:Receptors, CXCR3; C026777:ICI 118551; D016899:Interferon-beta; D010047:Ovalbumin; D011433:Propranolol; D015784:Betaxolol